 The mammalian target of rapamycin, MTOR, is a protein kinase that controls cellular metabolism, immune responses, autophagy, survival, proliferation, and migration to maintain cellular homeostasis through two distinct multisubunit complexes named MTORC12. The constitutive activation of the MTOR pathway due to mutations amplification deletion in either MTOR and its complexes or upstream targets is responsible for aging, neurological diseases, and human malignancies. Therapeutic targeting of MTOR signaling with improved anticancer efficacy has the potential to benefit cancer patients in clinics. This article was authored by Vivek Panwar, Eswaya Singh, Manini Bhatt, and others.